摘要
目的评价伊立替康联合对症支持疗法在不能耐受联合化疗的转移性结直肠癌患者治疗中的临床疗效及不良反应。方法选取我院原发肿瘤、淋巴结及远处转移（TNM）分期均为Ⅳ期的结直肠癌患者共24例，卡氏行为状态评分为40-60分，完全随机将患者分为观察组（13例）和对照组（11例）。观察组患者第1、8天给予伊立替康125mg／m^2静脉滴注，30-90min内滴完，联合对症支持治疗；对照组患者单纯给予对症支持治疗。观察2组患者临床疗效和不良反应发生情况。结果观察组治疗有效率为15．4％（2／13），疾病控制率53．8％（7／13）；对照组治疗有效率为0，疾病控制率为8．2％（2／11）。治疗1年后随访。观察组患者的生存率高于对照组[53．8％（7／13）比27．3％（3／11），P〈0．05]。治疗后，观察组生存质量提高患者的比率高于对照组，差异有统计学意义[53．8％（7／13）比27．3％（3／11），P〈0．05]。化疗的不良反应大多数患者可耐受，并未因此中断治疗。结论与单纯给予对症支持治疗相比，伊立替康联合支持治疗可以改善不能耐受联合化疗的转移性结直肠癌患者的疾病控制率，提高患者生存率和生活质量，且患者耐受性和依从性好。
Objective To evaluate the clinical efficacy and the toxicity of irinotecan combined with suitable-symptom nutritional supporting treatment for patients with advanced metastatic colorectal cancer who were intolerant of chemotherapy. Methods Twenty-four patients with tumor node metastases （TNM） stage 1V advanced metastatic colorectal cancer were enrolled, and their Karnofsky performance status （KPS） score was 40-60. The observation group had 13 cases and the control group was 11 cases. The observation group was treated by irinotecan and suitable-symptom nutritional support; the control group was treated by suitable-symptom nutritional support. Results Tumor response rate of patients was 15.4% （2/13） in the observation group; the disease control rate was 53.8% （7/13）. Survival rate of 1-year in the observation group was higher than that in the control group[ 53.8 （7/ 13 ） vs 27. 3 （3/11 ）, P 〈 0. 05 ] ; KPS increasing rate was higher than that of the control group [ 53. 8 （ 7/13 ） vs 27.3 （3/11 ）, P 〈 0. 05 ]. Adverse chemotherapy reaction was tolerable. Conclusions Disease control rate and 1- year survival rate in the observation group are significantly higher than those in the control group in advanced metastatic colorectal cancer. It can improve life quality. Patient tolerance and compliance are satisfactory.
出处
《中国医药》
2012年第10期1254-1256,共3页
China Medicine
关键词
转移性结直肠癌
伊立替康
对症支持治疗
Advanced metastatic colorectal cancer
Irinotecan
Suitable-symptom nutritional support
